Rep. Price sits on the House Ways and Means Subcommittee on Health that is responsible for crafting healthcare-facing legislation. While holding that role, he invested in:
- Indianapolis’ Eli Lilly
- New York’s Bristol-Meyers Squibb
- Deerfield, Ill.-based Amgen
- San Francisco’s McKesson
- Cambridge, Mass.-based Biogen
- New York’s Pfizer.
Last March, CMS proposed a rule that would change the incentives for prescribing physicians in an attempt to lower Medicare reimbursements from 6 percent of the price of a drug to 2 percent in addition to a small flat fee. Rep. Price opposed the change and co-sponsored legislation that would block the change if it were ever enforced, according to the report.
Rep. Price says a fund manager made the investments and stated plans to divest the stocks after confirmation.
https://www.beckersasc.com/asc-turnarounds-ideas-to-improve-performance/the-43-companies-rep-tom-price-plans-to-divest-after-confirmation-as-hhs-secretary-and-3-he-would-keep.html
More articles on improving health:
The Orthopedic Surgery Center of Arizona’s Dr. David Bailie becomes Integrated Endoscopy CMO, chairman: 5 key notes
5 tips for ASCs to increase revenue and streamline operations
7 things for ASC leaders to know — Jan. 17, 2017
